FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Dosed the first patient with its B7-H3 ADC and signed a definitive ADC platform agreement with Samsung Bioepis.

  • Announced that the first patient was dosed in the Phase 1 trial of ITC-6146RO. Source
  • Presented its definitive agreement with Samsung Bioepis and new payload and linker technologies. Source

Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

IntoCell

Develops antibody-drug conjugate (ADC) platform technologies, such as the OHPAS linker that keeps the drug stable in blood and releases it inside cancer cells, and its own ADC candidates.

OHPAS

Technology platform

ADC linker technology designed for stability in blood and selective drug release inside tumors.

ITC-6146RO

Phase 1

ADC targeting B7-H3, in a Phase 1a trial at three major Korean hospitals in patients with solid tumors after standard therapy.

iso-NxT

Technology platform

New payload technology; the company reported more than four times the tumor suppression of Enhertu at the same dose in an outsourced preclinical study.

Completion reported

Signed a definitive ADC platform agreement with Samsung Bioepis for the first target.

Completion reported

Dosed the first patient in the Phase 1 trial of ITC-6146RO.

Official role guide

IntoCell careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page was found, but postings and duties were not read in this check.
Experience & requirements
Unconfirmed — Requirements were not checked on the official careers page.

Information from a role guide does not establish a current vacancy.

Sources & coverage 3

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 인투셀, ADC 신약 'ITC-6146RO' 글로벌 임상 1상 본격화 ↗아시아경제 · Published 2026-03-24 · Sources checked 2026-11-18 · Original unavailable
  2. "삼성바이오에피스 다음은 글로벌"...인투셀, ADC 신기술로 L/O 확대 ↗파이낸셜뉴스 · Published 2026-08-19 · Sources checked 2026-11-18 · Original unavailable
  3. 채용 ↗인투셀 · Published Date unconfirmed · Sources checked 2026-11-18 · Original unavailable